BioSpace News Archive

Centers for Medicare and Medicaid Services announced that it updated its lung cancer screening eligibility guidelines for people covered by Medicare to be similar to the U.S.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage gamma-delta T cell therapies biopharmaceutical company today announced that Company executives will be presenting at the following events.

Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the virtual 11th Annual SVB Leerink Global Healthcare Conference.

Surgalign Holdings, Inc. announced the pricing of its previously announced underwritten public offering of 43,478,264 shares of its common stock and warrants to purchase up to an aggregate of 32,608,698 shares of common stock at a combined effective public offering price of $0.46 per share of common stock and accompanying 0.75 of a warrant.

Jaguar Health, Inc., under its Jaguar Animal Health tradename for the veterinary market, announced that it has completed filing of the final major regulatory section with the U.S. Food and Drug Administration’s Center for Veterinary Medicine to support conditional new animal drug approval of the company’s oral plant-based drug candidate Canalevia to treat exercise-induced diarrhea in dogs.

Kinetic River Corp., a leader in development of advanced flow cytometry technology, announced today the successful completion of a Phase II Small Business Innovation Research (SBIR) project funded by the National Institutes of Health (NIH).

Apollo Endosurgery, Inc., a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that the Company is scheduled to release financial results for the fourth quarter and full year ended December 31, 2021 on Tuesday, February 22, 2022, after market close.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial results and business highlights.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, the company’s President and Chief Executive Officer, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference.

Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced the appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors effective immediately.